Subscribe to
our newsletters

Subscribe to our newsletters!

Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.

Search in Nordic Life Science Insight

-
June 19, 2017
Spago Nanomedical

SpagoPix promising results in toxicological pilot studies

Collective data from recently completed toxicity studies show that the product candidate SN132D can be given safely at doses that widely exceeds the expected clinical dose.

SpagoPix promising results in toxicological pilot studies

Collective data from recently completed toxicity studies show that the product candidate SN132D can be given safely at doses that widely exceeds the expected clinical dose.

At the end of 2016, Spago Nanomedical formally announced its product candidate in the SpagoPix project. The product candidate, designated SN132D, has now been investigated in several preclinical pilot studies in order to reduce risk and prepare for the regulatory safety program prior to clinical studies.

The pilot studies has been performed as a series of in vivo experiments where acute- and sub-acute toxicology has been investigated at different doses of SN132D. Analyses includes e.g. hematological factors, as well as histological evaluation of vital organs. All data from the pilot studies collectively support the safety of SN132D at doses that widely exceed the expected clinical dose.

SN132D has also been subject to pilot testing in a cell-based system for mutagenicity, known as Ames test, where SN132D were significantly free of genotoxicity.

“Overall, these results means another risk reduction in the SpagoPix project and an important piece for the conduct of the regulatory preclinical program” says Oskar Axelsson, CSO of Spago Nanomedical.

For further information, contact Mats Hansen, CEO Spago Nanomedical AB, +46 767 764294, mats.hansen@spagonanomedical.se.

Last updated:
June 20, 2017

Spago Nanomedical

Spago Nanomedical AB is a Swedish company performing research and development within nanomedicine. Focus is the development of nanomaterials for tumor diagnostics and treatment of cancer. The main development projects SpagoPix and Tumorad are both built on proprietary nanomaterials

Click here to read more about us!
Get in touch with us!
Visit us

Scheelevägen 22
SE-223 63 Lund
Sweden

Send us mail

At the end of 2016, Spago Nanomedical formally announced its product candidate in the SpagoPix project. The product candidate, designated SN132D, has now been investigated in several preclinical pilot studies in order to reduce risk and prepare for the regulatory safety program prior to clinical studies.

The pilot studies has been performed as a series of in vivo experiments where acute- and sub-acute toxicology has been investigated at different doses of SN132D. Analyses includes e.g. hematological factors, as well as histological evaluation of vital organs. All data from the pilot studies collectively support the safety of SN132D at doses that widely exceed the expected clinical dose.

SN132D has also been subject to pilot testing in a cell-based system for mutagenicity, known as Ames test, where SN132D were significantly free of genotoxicity.

“Overall, these results means another risk reduction in the SpagoPix project and an important piece for the conduct of the regulatory preclinical program” says Oskar Axelsson, CSO of Spago Nanomedical.

For further information, contact Mats Hansen, CEO Spago Nanomedical AB, +46 767 764294, mats.hansen@spagonanomedical.se.

Last updated:
June 20, 2017

Spago Nanomedical

Spago Nanomedical AB is a Swedish company performing research and development within nanomedicine. Focus is the development of nanomaterials for tumor diagnostics and treatment of cancer. The main development projects SpagoPix and Tumorad are both built on proprietary nanomaterials

Click here to read more about us!
Get in touch with us!
Visit us

Scheelevägen 22
SE-223 63 Lund
Sweden

Send us mail